| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | Ascendis Pharma Introduces Vision 2030 | 451 | GlobeNewswire (Europe) | Strategic roadmap to achieve blockbuster status for multiple products and expand the Company's engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma... ► Artikel lesen | |
| 07.01. | Singular Genomics Systems, Inc.: Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue | 241 | GlobeNewswire (Europe) | SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers... ► Artikel lesen | |
| 07.01. | Amicus Therapeutics, Inc.: Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook | 675 | GlobeNewswire (Europe) | 2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16%... ► Artikel lesen | |
| 07.01. | Vincerx Pharma, Inc.: Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma | 320 | GlobeNewswire (Europe) | Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL)... ► Artikel lesen | |
| 07.01. | QIAGEN N.V.: QIAGEN announces plans to return approximately $300 million to shareholders | 867 | GlobeNewswire (Europe) | Venlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a plan to return up to approximately $300 million (maximum EUR 273... ► Artikel lesen | |
| 07.01. | Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance | 231 | GlobeNewswire (Europe) | CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for... ► Artikel lesen | |
| 07.01. | Pandora A/S: Pandora exceeds guidance: Strong Q4 sales lift full year organic growth to 8% | 605 | GlobeNewswire (Europe) | Following a strong end to 2023 with double-digit organic growth in the fourth quarter and solid profitability, the preliminary and unaudited results for 2023 exceed the full-year guidance communicated... ► Artikel lesen | |
| 07.01. | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones | 178 | GlobeNewswire (Europe) | Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million 2024 expected Total Revenue guidance... ► Artikel lesen | |
| 07.01. | Caribou Biosciences, Inc.: Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 | 253 | GlobeNewswire (Europe) | -- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate... ► Artikel lesen | |
| 07.01. | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance | 337 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery... ► Artikel lesen | |
| 07.01. | Akoya Biosciences, Inc.: Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform | 177 | GlobeNewswire (Europe) | MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described... ► Artikel lesen | |
| 07.01. | Akoya Biosciences, Inc.: Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook | 254 | GlobeNewswire (Europe) | MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter... ► Artikel lesen | |
| 07.01. | Gentex Corporation: Gentex Announces eSight Acquisition Set to Showcase Advanced Vision Tech at CES 2024 | 385 | GlobeNewswire (Europe) | LAS VEGAS, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX) announced today the asset acquisition of eSight, a leading provider of vision enhancement technologies, to develop and... ► Artikel lesen | |
| 07.01. | Akoya Biosciences, Inc.: Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow | 463 | GlobeNewswire (Europe) | MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 1.682 |
| NEL | 1.667 |
| SUPER MICRO COMPUTER | 1.656 |
| NVIDIA | 1.649 |
| TUI | 1.484 |
| BAYER | 1.336 |
| RHEINMETALL | 1.000 |
| RENK GROUP | 930 |
| PROSIEBENSAT.1 | 912 |
| VOLKSWAGEN | 735 |
| AMAZON | 699 |
| PALANTIR TECHNOLOGIES | 698 |
| TESLA | 687 |
| MICROSTRATEGY | 636 |
| DEUTSCHE BANK | 584 |
| PLUG POWER | 571 |
| BASF | 565 |
| BYD | 557 |
| THYSSENKRUPP | 542 |
| COMMERZBANK | 535 |
| AIXTRON SE | 532 |
| SAP | 507 |
| MERCEDES-BENZ | 506 |
| ALLIANZ | 493 |
| DEUTSCHE TELEKOM | 473 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
